

sought to describe morbidity and behavioural characteristics of these cases to better understand trends among this population.

Methods Data were gathered using clinic-based sentinel surveillance systems and through abstraction of Interview Records completed upon DIS interview.

Results Transgender women represented an increasing proportion of total syphilis cases identified from 2009 (3.7% or 10/269) to 2010 (6.4% or 20/313). The 20 cases identified in 2010 were among 19 transgender women; one client was re-infected. Of these, 2 (10%) were primary, 12 (60%) were secondary, 5 (25%) were early latent, and 1 (5%) was latent of unknown duration syphilis. The mean age increased slightly from 21.4 years (range 19–24) in 2009 to 24.9 years (range 19–41) in 2010. Reported race/ethnicity included: 13 (65%) non-Hispanic black, 3 (15%) Hispanic, 2 (10%) non-Hispanic white, 1 (5%) Asian/Pacific Islander and 1 (5%) American Indian/Alaskan Native. HIV co-infection was similar to rates observed in Men who Have Sex with Men (MSM) populations (60%); 25% of HIV-positive clients had been diagnosed in the prior year. Forty-five per cent had a history of STI (non-HIV). High rates of transient housing (30%), unemployment (55%), incarceration (25%), and transactional sex (40%) in the prior 12 months were reported. Median number of sex partners in the past year was 10 (range 0–60). No common sex partners were named during case investigation interviews during 2009 or 2010.

Conclusions Increases in syphilis among transgender women in Chicago highlight a need for enhanced screening and targeted prevention messages for this population. High levels of risk and HIV co-infection reflect potential for ongoing transmission of both HIV and other STIs.

LBO-1.4 INCREASING MACROLIDE RESISTANCE IN *MYCOPLASMA GENITALIUM*

doi:10.1136/sextrans-2011-050119.4

¹C Anagrus, ¹B Loré, ²J S Jensen. ¹Falu Hospital, Falun, Sweden; ²SSI, Köpenhamn, Denmark

Background To evaluate therapy outcome in *M genitalium* infection with standard chlamydia treatment doxycycline 9 days and azithromycin 1 g stat compared to extended azithromycin 15 g for 5 days and to evaluate macrolide resistance.

Methods Patients attending the STD-clinic in Falun, Sweden between January 1998 and December 2005 with a positive PCR test

for *M genitalium* routinely had a test of cure. Response was determined to doxycycline, azithromycin 1 g as a single dose and 15 g extended treatment primary and secondary when persistence after doxycycline. Macrolide resistance was monitored at base as well as after treatment in those testing positive after treatment with azithromycin. Macrolide resistance also was monitored yearly 2006–2010 in patients with newly detected *M genitalium* infection.

Results Totally 313/407 (77%) had a test of cure, 254/313 (81%) within 12 weeks. The eradication rate with doxycycline was 43% totally, 46% for women and 38% for men, with azithromycin 1 g 92% totally, 96% for women and 89% for men and with azithromycin extended dosage 96% totally, 100% for women and 93% for men. Confirmed macrolide resistance developed in 7/7 (100%) of those testing positive after azithromycin 1 g. In 2006–2007 we found no, in 2008 and 2009 1/year and in 2010 11 patients with macrolide resistance in newly detected *M genitalium*.

Conclusions These findings confirms the results from other studies that doxycycline is inefficient in eradicating infection with *M genitalium*. Although the treatment outcome with azithromycin 1 g was not significantly lower than with extended dosage for 5 days it was in this study associated with 100% induced macrolide resistance in those with treatment failure. A remarkable higher proportion of macrolide resistance in 2010 than earlier years was found. We will try to monitor yearly prescription of azithromycin 1 g in our county and all Sweden last years. Is there an increase explaining the higher proportion 2010? Azithromycin 1 g should be avoided as recommended therapy for *M genitalium* as well as for chlamydia and non-gonococcal urethritis. Specific diagnostics for *M genitalium* as well as monitoring of resistance is urgent.

LBO-1.5 MEN WHO HAVE SEX WITH MEN (MSM) HAVE A 140-FOLD RISK FOR HIV AND SYPHILIS COMPARED WITH OTHER MEN IN NEW YORK CITY

doi:10.1136/sextrans-2011-050119.5

¹P Pathela, ¹S Braunstein, ²J Schillinger, ¹C Shepard, ¹M Sweeney, ²S Blank. ¹NYC Department of Health and Mental Hygiene, Queens, New York, USA; ²Centers for Disease Control and Prevention, Queens, New York, USA

Background While men who have sex with men (MSM) comprise the majority of new HIV and new syphilis cases in the U.S.,

Abstract LBO-1.5 Table 1 Annual HIV Incidence among 229 HIV-Negative Men who Have Sex with Men (MSM) Diagnosed with Rectal Chlamydia or Gonorrhoea at New York City STD Clinics Between January 2008 and December 2009

	Number of patients	%	Person-years at risk	Number of HIV seroconversions by STD clinic diagnoses	Total number of HIV seroconversions after HIV registry cross-match	Annual HIV incidence	95% CI
Overall	229	100%	368.29	16	22	5.97	3.84 to 8.90
Age (years)							
<20	25	11%	37.07	4	4	10.79	3.42 to 26.00
20–29	148	65%	239.90	9	13	5.42	3.01 to 9.03
30–39	42	18%	69.56	2	5	7.19	2.63 to 15.93
40+	14	6%	21.75	0	0		
Race/ethnicity							
Non-Hispanic White	71	31%	116.63	2	3	2.57	0.65 to 7.00
Non-Hispanic Black	44	19%	63.44	6	9	14.19	6.92 to 26.03
Hispanic	83	36%	135.40	5	5	3.69	1.35 to 8.18
Asian	12	5%	20.23	1	1	4.94	0.25 to 24.38
Other/multiple	19	8%	32.59	1	4	12.27	0.15 to 15.13
Rectal infection							
Chlamydia	158	69%	252.62	10	14	5.54	3.15 to 9.08
Gonorrhoea	49	21%	80.85	4	5	6.18	2.27 to 13.71
Both	22	10%	34.82	1	3	8.62	2.19 to 23.45
Early syphilis concurrently or in last 2 years							
Yes	31	14%	50.33	3	4	7.95	2.52 to 19.17
No	198	86%	317.96	12	18	5.66	3.46 to 8.77

understanding the full burden of disease among them has been challenging as direct estimates of Men who Have Sex with Men (MSM) numbers in the general population have been largely unavailable. We describe the population of Men who Have Sex with Men (MSM) in New York City, compare their demographics, risk behaviours, and new HIV and primary and secondary (P&S) syphilis rates with those of men who have sex with women (MSW), and examine trends in disease rates among Men who Have Sex with Men (MSM).

Methods Population denominators and demographic and behavioural data were obtained from population-based behavioural surveys during 2005–2008. Numbers of new HIV and P&S syphilis diagnoses were extracted from citywide disease surveillance registries. We calculated overall, age- and race/ethnicity-specific case rates and rate ratios for Men who Have Sex with Men (MSM) and MSW, and analysed trends in Men who Have Sex with Men (MSM) rates by age and race/ethnicity.

Results The average prevalence of same-sex behaviour among sexually active men during 2005–2008 (5.0%; 95% CI 4.5 to 5.6) differed by age (peaking at 8% among 40–49-year-old men) and race/ethnicity (2.3% among non-Hispanic black men; 7.4% among non-Hispanic white men). Compared to MSW, Men who Have Sex with Men (MSM) differed significantly on all demographics and reported a higher prevalence of condom use at last sex and of HIV testing, but also more sex partners; 38.4% of Men who Have Sex with Men (MSM) and 13.6% of MSW reported ≥3 partners in the last year ($p < 0.001$). Men who Have Sex with Men (MSM) HIV and P&S syphilis rates were 2526.9/100 000 and 707.0/100 000, each of which was over 140 times MSW rates. Rates were highest among young and black Men who Have Sex with Men (MSM) (See Abstract LBO-1.5 table 1). Over 4 years, HIV rates more than doubled and P&S syphilis rates increased sixfold among 18–29-year-old Men who Have Sex with Men (MSM) to reach 8870.0/100 000 and 2900.4/100 000 in 2008, respectively.

Conclusions The substantial population of Men who Have Sex with Men (MSM) in NYC is at high risk for transmission of sexually transmitted infections given high disease rates and ongoing risk behaviours. There is significant overlap between HIV and P&S syphilis epidemics in NYC with the relatively small subgroups of young and non-Hispanic black Men who Have Sex with Men (MSM) disproportionately affected. Integration of HIV and STD case data would allow for better identification and characterisation of the population affected by these synergistic epidemics. Intensified and innovative efforts to implement and evaluate prevention programs are required.

LBO-1.6 EFFICACY OF THE QUADRIVALENT HPV VACCINE TO PREVENT ANAL INTRAEPITHELIAL NEOPLASIA AMONG YOUNG MEN WHO HAVE SEX WITH MEN

doi:10.1136/sextrans-2011-050119.6

S Goldstone. *Albert Einstein College of Medicine, New York, USA*

Introduction Most anal cancers are associated with HPV, particularly HPV 16. The incidence of anal cancer is increased among men who have sex with men (MSM) compared with the general population. Screening and treatment of anal intraepithelial neoplasia (AIN), the anal cancer precursor, are not yet standard of care, and prevention efforts are needed to reduce the incidence of anal cancer. We tested the quadrivalent HPV vaccine to determine its ability to reduce the incidence of AIN/anal cancer.

Methods 598 MSM aged 16–26 years with five or fewer lifetime sex partners were randomised to receive vaccine or placebo at enrolment, month 2 and month 6. Subjects underwent detailed anogenital exams and HPV sampling from the penis, scrotum, perineal/perianal and anal canal at enrolment, month 7 and at 6-month intervals

afterwards. Efficacy analyses were performed in a per-protocol (PPE) population (sero-negative and DNA-negative from day 1 through month 7 to the relevant vaccine HPV type) and in all enrollees in an intent-to treat (ITT) analysis. Median follow-up of the PPE population was 2.5 years (post-dose 3).

Results Vaccine efficacy against HPV 6/11/16/18-related AIN and anal cancer in the PPE population was 77.5% (95% CI 39.6 to 93.3) (5 vaccine cases vs 24 placebo cases). Efficacy against high-grade AIN (AIN 2+) was 74.9% (95% CI 8.8 to 95.4). In the ITT population the efficacy was 50.3% (95% CI 25.7 to 67.2) and 54.2% (95% CI 18.0 to 75.3), respectively. No anal cancer was seen in either treatment group.

Conclusions These results demonstrate that the quadrivalent HPV vaccine is efficacious in preventing AIN related to HPV 6/11/16/18 in MSM subjects naïve to vaccine HPV types at enrolment, as well as in an ITT population. The quadrivalent HPV vaccine may be a useful measure to reduce the incidence of anal disease in at-risk populations.

Late breaker poster session

LBP-1.01

THE INTERDICTION PROJECT: AN INNOVATIVE PROGRAM FOR HIV + PERSONS TO REDUCE HIV AND STD CO-INFECTION AND IMPROVE HIV TREATMENT OUTCOMES PHASE II

doi:10.1136/sextrans-2011-050119.7

S Frimpong, M Wilson, L M Mitchell-Samon, T Azarian. *Duval County Health Department*

Background/Objectives STD/HIV field investigations and the initial findings of Interdiction Project reveal that some persons with HIV infection have unprotected sex, multiple anonymous sex partners, and don't disclose their HIV status. Consistent condom use is low; recurrent co-infection with STDs and HIV transmission to sex partners is high. The Interdiction Project is a clinic-based, individual-level HIV intervention that combines linkage for treatment adherence/risk reduction education and testing with ongoing monitoring of patient care and epidemiologic data system. This project targets HIV positive persons who present with a new STD or history of unprotected sex.

Methods This is a prospective STD intervention follow-up study of 69 patients referred by HIV/AIDS and STD clinic providers and STD/HIV investigation specialist. Project staff conducted initial HIV/AIDS and STD transmission prevention and treatment monitoring knowledge plus risk assessment, intensive practical STD and HIV/AIDS health education, condom negotiation, condom skill training, sex partner elicitation for rapid HIV testing and linkage to care. STD and STD morbidity rates 18 months prior to follow-up were compared to 18 months of follow-up after referral. We analysed follow-up data to determine the STD rates, undetectable HIV viral loads and how Interdiction Project may help reduce the spread of HIV and STD co-infections.

Results Initial findings revealed high STD morbidity since HIV diagnosis and 26 clients had 48 STDs before referral. Overall STD rate was 50.7% (35/69) at referral, 14% consistent condom use always but 96% intend to use condoms and sex partner HIV positivity rate was 30% (6/20). HIV genotype resistance was 34% (14/41). At 18 months of follow-up, significant overall STD morbidity rate reduced from 74.3% to 25.4%, RR 0.34 (95% CI 0.22 to 0.52) and RR of STD reduced from 72.5% to 23.2%, RR 0.32 (95% CI 0.20 to 0.50). Achieving higher perfect knowledge score from pre- to post-education knowledge assessment correlated with reduction in STD and STD morbidity. Significant STD rates reduction was noted for many risk categories. Clients who had undetectable viral load on HAART increased from 50% (17/34) at referral to 88.2% (30/34) at 6–9 months and 77.4% (24/31) from 13 to 18 months of follow-up.